Vicarious Surgical Inc. (NYSE:RBOT) reported that its Chief Technology Officer, Sammy Khalifa, sold a total of 3,863 shares of the company's Class A Common Stock on March 20, 2024. The shares were sold at a weighted average price of $0.3407, with transaction prices ranging from $0.3294 to $0.3486 per share, amounting to over $1,300 in total value.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units granted to Khalifa on November 23, 2021. Following the transaction, Khalifa remains a significant shareholder of the company, retaining 1,215,977 shares of Vicarious Surgical Inc.
Investors and security holders may request detailed information about the sales, including the number of shares sold at each separate price, from the company or the Securities Exchange Commission, as indicated in the footnotes of the SEC filing.
The transaction comes at a time when the medical technology company continues to innovate in the field of robotic surgery. Vicarious Surgical Inc. specializes in orthopedic, prosthetic, and surgical appliances and supplies, with a focus on developing technologies that aim to improve patient outcomes and the efficiency of surgical procedures.
The executive's sale of shares is a routine financial move often observed among company insiders, reflecting personal financial management rather than a change in the company's business outlook. Shareholders of Vicarious Surgical Inc. may follow such transactions as part of their investment considerations.
InvestingPro Insights
As Vicarious Surgical Inc. (NYSE:RBOT) navigates the competitive landscape of medical technology, particularly in the domain of robotic surgery, the company's financial health and stock performance are pivotal for investors. A glance at the company's real-time data from InvestingPro reveals a market capitalization of $63.27 million, reflecting its current valuation in the market. With a Price to Book ratio for the last twelve months as of Q4 2023 standing at 0.66, it suggests that the stock is potentially undervalued relative to its assets.
However, the financial metrics also indicate challenges. The company's P/E Ratio, adjusted for the last twelve months as of Q4 2023, is at -0.92, underscoring that the company is not currently profitable. Additionally, Vicarious Surgical has experienced a 1 Year Price Total Return of -85.97%, which could be a concern for long-term investors. This is in line with one of the InvestingPro Tips that notes the stock price has fallen significantly over the last year.
Another InvestingPro Tip worth noting for investors is that analysts have recently revised their earnings upwards for the upcoming period. This could signal a potential shift in the company's trajectory or market perception. For investors looking for more comprehensive analysis and additional InvestingPro Tips, there are 11 more tips available for Vicarious Surgical Inc. on the InvestingPro platform. Interested investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which could provide deeper insights into the company's future performance and valuation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.